Claude Sonnet 5 Autonomously Selects Gene Therapy and Performs Mouse Brain Surgery
Understand the story
According to a report by The Decoder on October 31, 2026, Gabriel Ocana-Santero, a University of Oxford PhD student and co-founder of Exin Therapeutics, said that Claude Sonnet 5 autonomously selected the drug, brain region, and injection coordinates from 19 candidate gene therapies, and used custom electric surgical equipment to perform in vivo brain gene therapy surgery on an epileptic mouse. During the surgery, the model made 32 observations via camera, and the mouse reportedly recovered well after the operation. The report says Claude Sonnet 5 refused to continue midway through the surgery due to safety restrictions. The information currently comes from a single-source report, with no independent verification or follow-up official statement.
AI overview of reporting · Updated 3 h前
Reporting timeline
Explore different aspects of the story through its reporting.
- The DecoderA Claude model autonomously chose a gene therapy and operated on a mouse brain with no human decision-making
Gabriel Ocana-Santero, a University of Oxford PhD student and co-founder of Exin Therapeutics, said Claude Sonnet 5 autonomously selected the drug, brain region, and injection coordinates from 19 candidate gene therapies, then used custom electric surgical equipment to perform in vivo surgery on epileptic mice, making 32 observations via camera during the procedure; the mice recovered well.
Story heat trend
Current heat9·Comparable peak10（10/31 04:00）·Comparable change over 24 hours –
The trend compares the same continuously observed sources, which may cover fewer sources than the current heat score. Hover or select the chart to inspect each hour; use the left and right arrow keys to navigate.